KIRSTY 100 UNIT
INSULIN ASPART : 100 UNIT · DIN 02520982 · BIOCON SDN.BHD
Health Canada status: APPROVED
What is KIRSTY?
KIRSTY 100 UNIT contains INSULIN ASPART : 100 UNIT. It is listed in the Health Canada Drug Product Database under DIN 02520982, held by BIOCON SDN.BHD, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as approved, status dated 07-May-2026. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02520982 |
|---|---|
| Brand name | KIRSTY |
| Generic / active ingredient | INSULIN ASPART : 100 UNIT |
| Manufacturer | BIOCON SDN.BHD |
| Strength | 100 UNIT |
| Dosage form | SOLUTION |
| Route of administration | SUBCUTANEOUS |
| Schedule | Schedule D |
| ATC code | A10AB05 INSULIN ASPART |
| AHFS class | 68:20.08 |
| Biosimilar | Yes |
| Health Canada status | APPROVED |
| Status date | 07-May-2026 |
What can be used instead?
Other Canadian products sharing ATC code A10AB05 INSULIN ASPART. 8 of 11 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| FIASP | 100 UNIT | SOLUTION | NOVO NORDISK CANADA INC | MARKETED | DIN 02460408 |
| FIASP | 100 UNIT | SOLUTION | NOVO NORDISK CANADA INC | MARKETED | DIN 02460416 |
| KIRSTY | 100 UNIT | SOLUTION | BIOCON SDN.BHD | MARKETED | DIN 02520974 |
| NOVORAPID | 100 UNIT | SOLUTION | NOVO NORDISK CANADA INC | MARKETED | DIN 02245397 |
| NOVORAPID | 100 UNIT | SOLUTION | NOVO NORDISK CANADA INC | MARKETED | DIN 02244353 |
| TRURAPI | 100 UNIT | SOLUTION | SANOFI-AVENTIS CANADA INC | MARKETED | DIN 02529254 |
| TRURAPI | 100 UNIT | SOLUTION | SANOFI-AVENTIS CANADA INC | MARKETED | DIN 02506564 |
| TRURAPI | 100 UNIT | SOLUTION | SANOFI-AVENTIS CANADA INC | MARKETED | DIN 02506572 |
| FIASP | 100 UNIT | SOLUTION | NOVO NORDISK CANADA INC | DORMANT | DIN 02460424 |
| NOVORAPID | 100 UNIT | SOLUTION | NOVO NORDISK CANADA INC | CANCELLED POST MARKET | DIN 02377209 |
Who else supplies INSULIN ASPART worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. INSULIN ASPART appears in 441 registered pack listings across 11 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.